Insider Purchases: Inside the Buy

Tag: BiotechGrowth

Split image showing Corcept Therapeutics stock volatility: one side with a red falling chart and FDA rejection stamp, the other with a green rising chart and glowing biotech lab vial, symbolizing high-risk, high-reward biotech investing.

CORT Stock 2026: FDA Rejection, Insider Buying… and a Brewing Short Squeeze?

Corcept Therapeutics just got hit with an FDA rejection—but insiders are buying millions and short interest is surging. With a profitable base business and major 2026 catalysts ahead, CORT may be one of the most explosive “binary bets” in biotech today.

Read entire article

Tags: Biotech Investing, Biotech Picks, Biotech Stocks, BiotechGrowth, BiotechInvesting, BiotechStocks, buy or sell CORT, Corcept Therapeutics, CorceptTherapeutics, CORT, CORT stock, FDA rejection, featured-insiders, FUNanc1al investing, Growth stocks, Healthcare investing, High risk high reward, hub-insiders, Insider buying, InsiderTrading, OvarianCancerResearch, Relacorilant, risks buying CORT, Short squeeze, ShortSqueeze, Stock analysis 2026, StockMarket2026, why buy CORT
Digital illustration of a cancer cell being zapped by electric fields, symbolizing Novocure’s Tumor Treating Fields and stock rebound hopes.”

Novocure (NVCR): From Electric Fields to Fighting Cancer — and Maybe Lifting Portfolios?

Novocure is zapping cancer cells with Tumor Treating Fields — and maybe giving investors a shock of opportunity. With insiders and institutions piling in, can NVCR rebound 94% from its crash? ⚡📈

 

Read entire article

Tags: Ashley Cordova, Biotech Investing, BiotechGrowth, CEO Ashley Cordova, CEO Buys, CEO Conviction, CEO insider buying, CEO Stock Purchase, CEOBuyIn, CEOConfidence, CFO Bought Shares, CFO Insider Buying, CFOBuyIn, Funanc1al Humor, funanc1al investing, Funanc1al Stocks, glioblastoma, high-risk biotech, high-risk high-reward biotech, insider buying, institutional investors, Novocure, NVCR stock, oncology stocks, pancreatic cancer, tumor treating fields